These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 20308366)
1. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile. Babakhani F; Seddon J; Robert N; Shue YK; Sears P Antimicrob Agents Chemother; 2010 Jun; 54(6):2674-6. PubMed ID: 20308366 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Karlowsky JA; Laing NM; Zhanel GG Antimicrob Agents Chemother; 2008 Nov; 52(11):4163-5. PubMed ID: 18725442 [TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948 [TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Scott LJ Drugs; 2013 Oct; 73(15):1733-47. PubMed ID: 24136090 [TBL] [Abstract][Full Text] [Related]
6. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Allen CA; Babakhani F; Sears P; Nguyen L; Sorg JA Antimicrob Agents Chemother; 2013 Jan; 57(1):664-7. PubMed ID: 23147724 [TBL] [Abstract][Full Text] [Related]
7. Fidaxomicin: in Clostridium difficile infection. Duggan ST Drugs; 2011 Dec; 71(18):2445-56. PubMed ID: 22141387 [TBL] [Abstract][Full Text] [Related]
8. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Babakhani F; Gomez A; Robert N; Sears P Antimicrob Agents Chemother; 2011 Sep; 55(9):4427-9. PubMed ID: 21709084 [TBL] [Abstract][Full Text] [Related]
9. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment. James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221 [TBL] [Abstract][Full Text] [Related]
10. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318 [TBL] [Abstract][Full Text] [Related]
11. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile. Babakhani F; Seddon J; Sears P Antimicrob Agents Chemother; 2014 May; 58(5):2934-7. PubMed ID: 24550338 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Swanson RN; Hardy DJ; Shipkowitz NL; Hanson CW; Ramer NC; Fernandes PB; Clement JJ Antimicrob Agents Chemother; 1991 Jun; 35(6):1108-11. PubMed ID: 1929250 [TBL] [Abstract][Full Text] [Related]
13. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Johnson S; Gerding DN; Louie TJ; Ruiz NM; Gorbach SL Antimicrob Agents Chemother; 2012 Aug; 56(8):4043-5. PubMed ID: 22615287 [No Abstract] [Full Text] [Related]
14. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum. Koon HW; Ho S; Hing TC; Cheng M; Chen X; Ichikawa Y; Kelly CP; Pothoulakis C Antimicrob Agents Chemother; 2014 Aug; 58(8):4642-50. PubMed ID: 24890583 [TBL] [Abstract][Full Text] [Related]
15. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Babakhani F; Gomez A; Robert N; Sears P J Med Microbiol; 2011 Aug; 60(Pt 8):1213-1217. PubMed ID: 21349983 [TBL] [Abstract][Full Text] [Related]
16. Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells. Chen C; Doll NK; Casadei G; Bremner JB; Lewis K; Kelso MJ Bioorg Med Chem Lett; 2014 Jan; 24(2):595-600. PubMed ID: 24360560 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ; J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839 [TBL] [Abstract][Full Text] [Related]
18. Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. Housman ST; Thabit AK; Kuti JL; Quintiliani R; Nicolau DP Infect Control Hosp Epidemiol; 2016 Feb; 37(2):215-8. PubMed ID: 26592763 [TBL] [Abstract][Full Text] [Related]
19. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166 [TBL] [Abstract][Full Text] [Related]
20. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin. Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]